Nikhil Yegya-Raman

Dr. Nikhil Yegya-Raman


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
NYNikhil Yegya-Raman
Nikhil Yegya-Raman
KWKyle Wang
Kyle Wang
SKSinae Kim
Sinae Kim
MRMeral Reyhan
Meral Reyhan
MDMatthew P. Deek
Matthew P. Deek
SJSalma Jabbour
Salma Jabbour

24 November 2023 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
CFCole Friedes
Cole Friedes
MIMichelle Iocolano
Michelle Iocolano
SLSang Ho Lee
Sang Ho Lee
LDLian Duan
Lian Duan
BLBolin Li
Bolin Li
NYNikhil Yegya-Raman
Nikhil Yegya-Raman

1 August 2018 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
NYNikhil Yegya-Raman
Nikhil Yegya-Raman
SKSinae Kim
Sinae Kim
MDMatthew P. Deek
Matthew P. Deek
DLDiana Li
Diana Li
AGApar Gupta
Apar Gupta
SJSalma Jabbour
Salma Jabbour

24 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
NSNishant Shah
Nishant Shah
NYNikhil Yegya-Raman
Nikhil Yegya-Raman
JJJoshua A. Jones
Joshua A. Jones
JSJacob E Shabason
Jacob E Shabason
The management of patients with metastatic cancer is rapidly changing. Historically, radiotherapy was utilized for the treatment of localized disease or for palliation. While systemic therapy remains the mainstay of management for patients with metastatic cancer, radiotherapy is becoming increasingly important not only to palliate symptoms, but also to ablate oligometastatic or oligoprogressive disease and improve local control in the primary site. There is emerging evidence in multiple solid malignancies that patients with low volume metastatic disease that undergo local ablative therapy to metastatic sites may have improved progression free survival and potentially overall survival. In addition, there is increasing evidence that select patients with metastatic disease may benefit from aggressive treatment of the primary site. Patients with metastatic soft tissue sarcoma have a poor overall prognosis. However, there may be opportunities in patients with low volume metastatic soft tissue sarcoma to improve outcomes with local therapy including surgery, ablation, embolization, and radiation therapy. Stereotactic body radiation therapy (SBRT) offers a safe, convenient, precise, and non-invasive option for ablation of sites of metastases. In this review article, we explore the limited yet evolving role of radiotherapy to metastatic and primary sites for local control and palliation, particularly in the oligometastatic setting.

15 November 2023 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
NYNikhil Yegya-Raman
Nikhil Yegya-Raman
SLSang Ho Lee
Sang Ho Lee
CFCole Friedes
Cole Friedes
XWXingmei Wang
Xingmei Wang
MIMichelle Iocolano
Michelle Iocolano
SFSteven J. Feigenberg
Steven J. Feigenberg

22 August 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
NYNikhil Yegya-Raman
Nikhil Yegya-Raman
CFCole Friedes
Cole Friedes
SLSang Ho Lee
Sang Ho Lee
MIMichelle Iocolano
Michelle Iocolano
LDLian Duan
Lian Duan
SFSteven J. Feigenberg
Steven J. Feigenberg